Please see below for frequently asked questions about the International Symposium on ALS/MND. If you can't find an answer to your question below, please do not hesitate to contact us.
The 30th International Symposium on ALS/MND in Perth 2019 was approved by the Federation of the Royal College of Physicians of the United Kingdom for 18 category 1 (external) CPD credits. More information for this year's 31st Symposium will be coming soon.
The 30th International Symposium on ALS/MND in Perth 2019, was accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 13 European CME credits (ECMEC®s). More information for this year's 31st Symposium will be coming soon.
Poster and Poster Prize information
Note that if there is a change in presenting author you must let us know as soon as possible by emailing firstname.lastname@example.org. This includes instances when someone is presenting on your behalf or you are no longer able to attend.
The Poster Prize is usually awarded to two presenting authors of the best biomedical and clinical posters. Find out more about eligibility on the Poster Prize page.
Posters should be paper size A0 (841 x 1189mm; size E by American National Standards Institute) in a portrait orientation.
We will recommend a site in Montreal closer to the date of the 31st Symposium.
The submission deadline for abstracts wwill be announced soon.
The Programme Committee will review all submitted abstracts during June. All corresponding authors will be notified about their abstract decision by the end of July.
Abstracts can usually be withdrawn before August, an exact date will be announced soon. Any abstracts withdrawn after this date will still be published in the journal supplement.
Abstracts for the platform and poster presentations will be published in the online only version of the ‘Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration’ journal supplement. Work in Progress/Care Practice abstracts will be available to download from our website as a PDF document and will not be published in the ALS&FD journal supplement.
The draft programme will be available on our website in early August.
Each year, we have one or two slots reserved for news on results. For example, from a Phase 3 clinical trial, new gene discovery or similar; these are highly competitive, and there is therefore no guarantee of securing a slot. A short abstract must be submitted no later than the end of September to email@example.com.
We do not offer a day rate, as delegates are expected to attend all three days of the conference.
There are no reduced rates for students. We advise that they register as soon as possible to get the early bird rate which will be confirmed soon.
People with MND will be charged the early bird (discounted) rate of £400 (which will be available throughout the year), and one accompanying carer will be able to attend for free. Please email firstname.lastname@example.org for more details.